The emergence of follow-on disease-modifying therapies for multiple sclerosis

2019 ◽  
Vol 25 (12) ◽  
pp. 1560-1565 ◽  
Author(s):  
Brandon P Moss ◽  
Jeffrey A Cohen
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Cost Savings ◽  
Cost Of Care ◽  
Regulatory Approval ◽  
New Drugs ◽  
Major Contributor ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis

Medication prices are a major contributor to the high cost of care for multiple sclerosis. Three generic glatiramer acetate products have regulatory approval in North America, Europe, or Latin America. The pending expiration of patents for other disease-modifying therapies for relapsing multiple sclerosis creates the opportunity for development and regulatory approval of additional follow-on alternatives (generics or biosimilars), potentially providing lower prices and cost savings to payors and patients. However, the complexities of development, regulatory approval, and marketing of follow-on products have some important differences compared to those of new drugs. This topical review provides background and a status update on the development of follow-on disease-modifying medications to treat multiple sclerosis.

scholarly journals Disease-modifying therapies in multiple sclerosis in Latin America

2017 ◽  
Vol 3 (3) ◽  
pp. 205521731772336 ◽  
Author(s):  
Eli Skromne-Eisenberg ◽  
Laura Ordoñez-Boschetti ◽  
Irene Treviño-Frenk
Keyword(s):  
Multiple Sclerosis ◽  
Latin America ◽  
Disease Modifying Therapies ◽  
Disease Modifying

Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies

2021 ◽  
Author(s):  
José Meca-Lallana ◽  
Juan Antonio García-Merino ◽  
Sergio Martínez-Yélamos ◽  
Angela Vidal-Jordana ◽  
Lucienne Costa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Decision Making ◽  
Expert Opinion ◽  
Second Line ◽  
High Efficacy ◽  
Clinical Evolution ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis ◽  
Selection Of

Relapsing multiple sclerosis (RMS) presents a highly variable clinical evolution among patients, and its management should be personalized. Although there is no cure at present, effective disease-modifying therapies (DMTs) are available. Selection of the most appropriate DMT for each patient is influenced by several clinical, radiological and demographic aspects as well as personal preferences that, at times, are not covered in the regulatory criteria. This may be a source of difficulty, especially in certain situations where so-called ‘high-efficacy DMTs’ (usually considered second-line) could be of greater benefit to the patient. In this narrative review, we discuss evidence and experience, and propose a pragmatic guidance on decision-making with respect to the indication and management of high-efficacy DMT in adult patients with RMS based on expert opinion.

scholarly journals Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

2020 ◽  
Vol 9 (18) ◽  
pp. 1255-1274
Author(s):  
Imtiaz A Samjoo ◽  
Evelyn Worthington ◽  
Christopher Drudge ◽  
Melody Zhao ◽  
Chris Cameron ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Meta Analysis ◽  
Relative Effect ◽  
Disability Progression ◽  
Disease Modifying Therapies ◽  
Annualized Relapse Rate ◽  
Progression Risk ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.

scholarly journals Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis

2019 ◽  
Vol 15 (1) ◽  
pp. 20 ◽  
Author(s):  
Su-Hyun Kim ◽  
Min Su Park ◽  
Woojun Kim ◽  
So-Young Huh ◽  
Hyun-June Shin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real World ◽  
Korean Patients ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis

Immunomodulatory Agents for Relapsing-Remitting Multiple Sclerosis

2016 ◽  
Author(s):  
Jessica F. Robb ◽  
Lawrence M. Samkoff
Keyword(s):  
Multiple Sclerosis ◽  
The United States ◽  
Immunomodulatory Agents ◽  
Disease Modifying Therapies ◽  
Therapeutic Algorithm ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Relapsing Multiple Sclerosis ◽  
The U.S

The treatment of multiple sclerosis has become much more complicated with the development of new oral and other disease-modifying therapies (DMT) that have been added to the formulary of older injectables and natalizumab. To date, twelve medications have been approved in the United States for use in cases of relapsing multiple sclerosis. Neurologists managing patients with multiple sclerosis must integrate numerous variables when selecting the appropriate agent for each individual. This chapter presents an overview of the DMTs currently approved by the U.S. Food and Drug Administration for multiple sclerosis and suggests a therapeutic algorithm to aid in choosing among these medications.

scholarly journals Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rosa C. Lucchetta ◽  
Magda L. Oliveira ◽  
Aline F. Bonetti ◽  
Fernando Fernandez-Llimos ◽  
Astrid Wiens
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Outcome Measures ◽  
Randomized Clinical Trials ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document